Yan Luo
AbbVie
20 Papers
40 Citations
Yan Luo is an academic researcher from AbbVie. The author has contributed to research in topics: Ombitasvir & Dasabuvir. The author has an hindex of 7, co-authored 16 publications.
Chat about Author
Papers
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma
Mark R. Middleton,Philip Friedlander,Omid Hamid,Adil Daud,Ruth Plummer,Nancy Falotico,Brenda Chyla,F. Jiang,Evelyn McKeegan,Nael M. Mostafa,Ming Zhu,Jane Qian,Mark D. McKee,Yan Luo,Vincent L. Giranda,Grant A. McArthur +15 more
TL;DR: Median PFS with 20 and 40 mg veliparib almost doubled numerically compared with placebo, but the improvements did not reach statistical significance.
88
Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Heidi J. Gray,Katherine M. Bell-McGuinn,Gini F. Fleming,Mihaela C. Cristea,Hao Xiong,Danielle Sullivan,Yan Luo,Mark D. McKee,Wijith Munasinghe,Lainie P. Martin +9 more
TL;DR: Combination therapy demonstrated promising preliminary antitumor activity in platinum-sensitive ovarian cancer patients with germline BRCA mutations andVeliparib plus carboplatin/gemcitabine is tolerated, with a safety profile similar tocarboplatin and gem citabine alone.
69
Phase I study of ABT-888 in combination with carboplatin and gemcitabine in subjects with advanced solid tumors.
Katherine M. Bell-McGuinn,Heidi J. Gray,Gini F. Fleming,Mihaela C. Cristea,Diane Medina,Hao Xiong,Matthew W. Dudley,Martin Dunbar,Vincent L. Giranda,Yan Luo,Mark D. McKee,Lainie P. Martin +11 more
TL;DR: The objectives of this study were to determine the maximum tolerated dose (MTD), pharmacokinetic interactions, and safety/tolerability profile of V in combination with carboplatin (C) and gemcitabine (G) and to assess tolerability of C/G prior to V.
14
P0847 : Malachite-II: Phase 3b trial of ombitasvir/paritaprevir/r and dasabuvir + ribavirin or telaprevir + peginterferon/ribavirin in peginterferon/ribavirin treatment-experienced adults with HCV genotype 1
Gregory J. Dore,Brygida Knysz,Yan Luo,Ewa Janczewska,Anca Streinu-Cercel,F.A. Caruntu,Adriana Motoc,Włodzimierz Mazur,David R. Shaw,István Tornai,Joe Sasadeusz,Richard Skoien,Danielle Sullivan,Xuan Liu,Thomas Podsadecki +14 more
7
Efficacy of Veliparib (ABT-888) Plus Temozolomide Versus Temozolomide Alone: a Randomized, Double-blind, Placebo-controlled Trial in Patients with Metastatic Melanoma
Mark R. Middleton,Philip Friedlander,Omid Hamid,Adil Daud,Ruth Plummer,R. Schuster,J. Qian,Yan Luo,Vincent L. Giranda,Grant A. McArthur +9 more
5